Evidence map›Paper›PMID 25660980›Full record

ArticleGastrointestinal endoscopy2015

EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses.

Larissa L Fujii-Lau, Barham K Abu Dayyeh, Marco J Bruno, Kenneth J Chang, John M DeWitt, Paul Fockens, David Forcione, Bertrand Napoleon, Laurent Palazzo, Mark D Topazian and 12 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastrointestinal endoscopy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Endoscopic ultrasound in chronic liver disease.World journal of hepatology · 2020
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 14 institutions in 3 countries.

Larissa L Fujii-LauDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Barham K Abu DayyehDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Marco J BrunoDepartment of Gastroenterology and Hepatology, Erasmus Medical Center, University Medical Center, Rotterdam, The Netherlands.
Kenneth J ChangDivision of Gastroenterology and Hepatology, University of California Irvine, Orange, California, USA.
John M DeWittDivision of Gastroenterology and Hepatology, Indiana University, Indianapolis, Indiana, USA.
Paul FockensDivision of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
David ForcioneDivision of Gastroenterology and Hepatology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Bertrand NapoleonDepartment of Gastroenterology, Private Hospital Jean Mermoz, Lyon, France.
Laurent PalazzoTracadero Clinic, Paris, France.
Mark D TopazianDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Maurits J WiersemaLutheran Medical Group, Fort Wayne, Indiana, USA.
Amitabh ChakDivision of Gastroenterology and Liver Disease, University Hospitals Case Medical Center, Cleveland, Ohio, USA.
Jonathan E ClainDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Douglas O FaigelDivision of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, USA.
Ferga C GleesonDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Robert HawesCenter for Interventional Endoscopy, Florida Hospital, Orlando, Florida, USA.
Prasad G IyerDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Elizabeth RajanDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Tyler StevensDepartment of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA.
Michael B WallaceDivision of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
Kenneth K WangDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Michael J LevyDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
WinnMed · USMayo Clinic · USAdventHealth Orlando · USCleveland Clinic · USErasmus MC · NLHôpital Privé Jean Mermo · FRIndiana University – Purdue University Indianapolis · USLutheran Medical Group · USMassachusetts General Hospital · USMayo Clinic in Arizona · USMayo Clinic in Florida · USUniversity Hospitals Case Medical Center · USUniversity of Amsterdam · NLUniversity of California, Irvine · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
NCATS NIH HHS UL1 TR000135
6 · The paper itself

Abstract

backgroundDetection of hepatic metastases during EUS is an important component of tumor staging.

objectiveTo describe our experience with EUS-guided FNA (EUS-FNA) of solid hepatic masses and derive and validate criteria to help distinguish between benign and malignant hepatic masses.

designRetrospective study, survey.

settingSingle, tertiary-care referral center. PATIENTS: Medical records were reviewed for all patients undergoing EUS-FNA of solid hepatic masses over a 12-year period.

interventionsEUS-FNA of solid hepatic masses. MAIN OUTCOME MEASUREMENTS: Masses were deemed benign or malignant according to predetermined criteria. EUS images from 200 patients were used to create derivation and validation cohorts of 100 cases each, matched by cytopathologic diagnosis. Ten expert endosonographers blindly rated 15 initial endosonographic features of each of the 100 images in the derivation cohort. These data were used to derive an EUS scoring system that was then validated by using the validation cohort by the expert endosonographer with the highest diagnostic accuracy.

resultsA total of 332 patients underwent EUS-FNA of a hepatic mass. Interobserver agreement regarding the initial endosonographic features among the expert endosonographers was fair to moderate, with a mean diagnostic accuracy of 73% (standard deviation 5.6). A scoring system incorporating 7 EUS features was developed to distinguish benign from malignant hepatic masses by using the derivation cohort with an area under the receiver operating curve (AUC) of 0.92; when applied to the validation cohort, performance was similar (AUC 0.86). The combined positive predictive value of both cohorts was 88%. LIMITATIONS: Single center, retrospective, only one expert endosonographer deriving and validating the EUS criteria.

conclusionAn EUS scoring system was developed that helps distinguish benign from malignant hepatic masses. Further study is required to determine the impact of these EUS criteria among endosonographers of all experience.

Indexed as

Endoscopic Ultrasound-Guided Fine Needle AspirationAgedEndosonographyFemaleHumansLiverLiver NeoplasmsMaleMiddle AgedNeoplasm StagingRetrospective Studies

Identifiers

PMID25660980
PMCPMC5574178
OpenAlexW1969523816

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.